Humanetics, a private biopharmaceutical company based in Minnesota, is seeking up to US$20M in a Series B to develop BYOGRAYZ™ (aka BIO 300), a selective ERβ agonist which has produced excellent results as a medical countermeasure (MCM) to treat Acute Radiation Sickness (fully funded through EUA), in preventing tissue damage from RT in oncology (Phase 2b-ready in NSCLC), and in mitigating impaired pulmonary function in Long COVID (results recently announced).
Address
ExcelsiorMinnesota
United States